- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04973163
Eine Studie zum Testen verschiedener Dosen von BI 1823911 allein und in Kombination mit anderen Arzneimitteln bei Menschen mit verschiedenen Arten von fortgeschrittenem Krebs mit KRAS-Mutation
Eine offene, multizentrische Dosiseskalations- und Expansionsstudie der Phase Ia/Ib zur Untersuchung der Sicherheit, Pharmakokinetik und vorläufigen Wirksamkeit von BI 1823911 als Monotherapie und in Kombination mit anderen Krebstherapien bei Patienten mit fortgeschrittenen oder metastasierten soliden Tumoren KRAS G12C-Mutation
This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists.
People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time.
The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose is used to find out whether BI 1823911 alone and in combination with BI 1701963 can make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it.
During this time, participants take tablets of BI 1823911 alone or in combination with BI 1701963 once a day. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participant's health.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Anderlecht/Brussels-Capital, Belgien, 1070
- Brussels - HOSP Jules Bordet
-
Edegem/Antwerpen, Belgien, 2650
- Universitair Ziekenhuis Antwerpen
-
Gent/Oost-Vlaanderen, Belgien, 9000
- Universitair Ziekenhuis Gent
-
Leuven/Vlaams-Brabant, Belgien, 3000
- UZ Leuven
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Sarah Cannon Research Institute at Mary Crowley
-
Houston, Texas, Vereinigte Staaten, 77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Manchester, Vereinigtes Königreich, M20 4BX
- The Christie
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Pathologically confirmed diagnosis of locally advanced or metastatic solid tumours, e.g. adenocarcinoma of the lung, colorectal cancer, pancreatic cancer or cholangiocarcinoma. Non-small cell lung cancer (NSCLC) patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
-
Documented disease progression despite appropriate prior standard therapies or for whom no standard therapy exists for their tumour type and disease stage.
-
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a validated test.
-
Provision of archival tumour tissue, if available, to confirm retrospectively KRAS G12C mutation status and for biomarker assessment.
-
At least one target lesion that can be measured per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 (radiated lesions do not qualify as target lesions). In patients who only have one target lesion, and a biopsy of the lesion is required, the baseline imaging must be performed before the biopsy or at the earliest two weeks after the biopsy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Adequate organ function as follows:
- Absolute neutrophil count (ANC) ≥1.5 x 10^9/L (equivalent values: ≥ 1.5 x 10³/μL or ≥ 1500/mm³); hemoglobin ≥9.0 g/dL (equivalent values: ≥ 90 g/L or ≥ 5.6 mmol/L); platelets ≥100 x 10^9/L (equivalent values: ≥ 100 x 10³/μL or ≥ 100 x 10³/mm³) without the use of haematopoietic growth factors.
- Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for patients who are known to have Gilbert's syndrome.
- Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥50 mL/min (equivalent value: 0.84mL/s) (measured or calculated by Cockcroft-Gault formula).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN, for patients with liver metastases ≤5 x ULN.
-
Age ≥18 years of age, or over the legal age of consent as required by local legislation.
Further inclusion criteria apply.
Exclusion Criteria:
- Previous anticancer chemotherapy within 3 weeks of the first administration of trial drug. Previous anticancer hormonal treatment or anticancer immunotherapy within 2 weeks of the first administration of trial drug.
- Previous treatment with Rat Sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or Son of sevenless 1 (SOS1) targeting agents (only for monotherapy Parts A, B, and C).
- Radiotherapy within 2 weeks prior to start of treatment, provided recovery from related toxicity.
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of treatment or planned during the projected course of the trial, e.g. hip replacement.
- Previous treatment with any investigational agent(s) or targeted treatment within 28 days prior to start of treatment or 5 half-lives, whichever is shorter.
- Known history of hypersensitivity to any of the excipients of BI 1823911 tablets, or any contraindication to Midazolam (for Monotherapy Part B only).
- History or presence of cardiovascular abnormalities such as congestive heart failure New York Heart Association (NYHA) classification of ≥3, unstable angina or poorly controlled arrhythmia which are considered clinically relevant by the Investigator. Myocardial infarction within 6 months prior to start of treatment. Uncontrolled hypertension defined as: Blood pressure (BP) measured in a rested and relaxed condition, where systolic BP >=140 mmHg, or diastolic BP >= 90 mmHg, with or without medication.
- Left ventricular ejection fraction (LVEF) <50%. Further exclusion criteria apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Monotherapy Arm
Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm |
|
Experimental: Combination Therapy Arm
Will be started after confirmation of safety in the Monotherapy Arm. Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C). |
BI 1823911 BI 1701963 |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Dose escalation (Part A) - Monotherapy and combination therapy: Number of patients experiencing Dose limiting toxicities (DLTs) during the Maximum tolerated dose (MTD) evaluation period for BI 1823911 in monotherapy and in each combination
Zeitfenster: up to 28 days
|
DLTs are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
up to 28 days
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR) defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR)
Zeitfenster: up to 39 months
|
BOR is determined according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Dosiseskalation (Teil A) – Monotherapie und Kombinationstherapie: Anzahl der Patienten, bei denen DLTs während aller Behandlungszyklen für BI 1823911 in Monotherapie und in jeder Kombination auftraten
Zeitfenster: bis 39 Monate
|
bis 39 Monate
|
|
|
Alle Studienteile: Anzahl der Patienten mit unerwünschten Ereignissen während der Behandlungsdauer
Zeitfenster: bis 39 Monate
|
bis 39 Monate
|
|
|
Alle Studienteile, BI 1823911: Höchstkonzentration (Cmax)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1823911: Steady State Konzentration (Css)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1823911: Fläche unter der Plasmakonzentrations-Zeit-Kurve vom Zeitpunkt Null bis zum Zeitpunkt t (AUCτ)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1823911: Fläche unter der Plasmakonzentrations-Zeit-Kurve im Steady State (AUCss)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1701963: Höchstkonzentration (Cmax)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1701963: Steady State Konzentration (Css)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1701963: Fläche unter der Plasmakonzentrations-Zeit-Kurve vom Zeitpunkt Null bis zum Zeitpunkt t (AUCτ)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Alle Studienteile, BI 1701963: Fläche unter der Plasmakonzentrations-Zeit-Kurve im Steady State (AUCss)
Zeitfenster: bis zu 24 Stunden
|
bis zu 24 Stunden
|
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Objective response (OR)
Zeitfenster: up to 39 months
|
OR is defined as best overall response (BOR) of complete response (CR) or partial response (PR), both regardless of confirmation. BOR is determined according to RECIST version 1.1. BOR will consider all tumour assessments from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Duration of OR
Zeitfenster: up to 39 months
|
Duration of OR is defined as the time from first documented CR or PR until disease progression or death (whichever occurs first) among patients with OR. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Tumour shrinkage (in millimetres)
Zeitfenster: up to 39 months
|
Tumour shrinkage is defined as the difference between the minimum post-baseline sum of diameters of target lesions (longest for non-nodal lesions, short axis for nodal lesions) and the baseline sum of longest diameters of the same set of target lesions. |
up to 39 months
|
|
Dose confirmation (Part B) and expansion (Part C) - Monotherapy and combination therapy: Progression-free survival (PFS) rate
Zeitfenster: at month 6
|
PFS is defined as the time from first treatment administration until tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs earlier. |
at month 6
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1472-0001
- 2021-000460-29 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .